MedTrace Logo

Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients

NCT00493896 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2022-04-11

No results posted yet for this study

Summary

This is a pilot study to evaluate safety of fondaparinux and enoxaparin in terms of bleeding and development of thrombocytopenia in the medical ICU population.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Fondaparinux

The dose for Arixtra is 2.5 mg once daily, subcutaneously.

DRUG

Enoxaparin

The dose for Lovenox is 40 mg once daily, subcutaneously.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Eastern Virginia Medical School

    lead OTHER

Principal Investigators

  • Charles W Callender, MD · Eastern VA Medical School, Norfolk, VA

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-04-30
Completion
2010-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493896 on ClinicalTrials.gov